Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07817563
PHASE1
A Phase I Single Center Study Evaluating 68GA-FAPI-46 PET/CT in Patients With Interstitial Lung Disease
Sponsor: Mayo Clinic
View on ClinicalTrials.gov
Summary
The purpose of this research is to better understand the distribution of an investigational radioactive imaging agent called 68Ga-FAPI-46 in the lungs of people with interstitial lung disease (ILD) during a Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-10-16
Completion Date
2031-05
Last Updated
2026-09-14
Healthy Volunteers
No
Conditions
Interventions
DRUG
⁶⁸Ga-FAPI-46
Subjects will have 68Ga-FAPI-46 intravenously administered
DIAGNOSTIC_TEST
PET/CT
Subjects will complete a PET/CT approximately 60-70 minutes after being given ⁶⁸Ga-FAPI-46
Locations (1)
Mayo Clinic
Rochester, Minnesota, United States